Dendreon (NASDAQ:DNDN) has posted its results. The actual EPS and revenues don’t matter because of the stage of the company. But the company did lower its total expenses to $23.4 million. That compares to $26.3 million from Q2 2006 and roughly $28 million last quarter. Those expenses included options costs of $1.3 million and $2.9 million, respectively.
So the company slowed its cash burn rate, and that is what we wanted to see. Unfortunately the company made no new developments in the "highlights" or "disclosures." Unless the company announces some unexpected FDA developments or unless it announces a surprise partner, this one sounds like there could be a continued news vacuum.
Jon C. Ogg
August 7, 2007
Jon Ogg can be reached at email@example.com; he does not own securities in the companies he covers.